Building on its retinal disease expertise, Regeneron signs eye-focused gene therapy pact with German biotech
Regeneron beefed up its gene therapy capabilities Wednesday, signing a new deal with the German biotech ViGeneron.
The similarly named — but unrelated — companies announced the collaboration early Wednesday morning, one which would see ViGeneron receive undisclosed upfront and milestone payments in exchange for Regeneron getting access to its suite of recombinant adeno-associated virus vectors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.